HUP0101666A3 - Methods of treating obesity using a neurotensin receptor ligand - Google Patents
Methods of treating obesity using a neurotensin receptor ligandInfo
- Publication number
- HUP0101666A3 HUP0101666A3 HU0101666A HUP0101666A HUP0101666A3 HU P0101666 A3 HUP0101666 A3 HU P0101666A3 HU 0101666 A HU0101666 A HU 0101666A HU P0101666 A HUP0101666 A HU P0101666A HU P0101666 A3 HUP0101666 A3 HU P0101666A3
- Authority
- HU
- Hungary
- Prior art keywords
- methods
- receptor ligand
- treating obesity
- neurotensin receptor
- neurotensin
- Prior art date
Links
- 102000017922 Neurotensin receptor Human genes 0.000 title 1
- 108060003370 Neurotensin receptor Proteins 0.000 title 1
- 208000008589 Obesity Diseases 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19995100P | 2000-04-27 | 2000-04-27 |
Publications (3)
Publication Number | Publication Date |
---|---|
HU0101666D0 HU0101666D0 (en) | 2001-06-28 |
HUP0101666A2 HUP0101666A2 (hu) | 2002-02-28 |
HUP0101666A3 true HUP0101666A3 (en) | 2003-03-28 |
Family
ID=22739686
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0101666A HUP0101666A3 (en) | 2000-04-27 | 2001-04-26 | Methods of treating obesity using a neurotensin receptor ligand |
Country Status (13)
Country | Link |
---|---|
US (1) | US6699832B2 (hu) |
EP (1) | EP1157695B1 (hu) |
JP (1) | JP2002275092A (hu) |
KR (1) | KR20010098829A (hu) |
AT (1) | ATE331518T1 (hu) |
AU (1) | AU3888801A (hu) |
CA (1) | CA2345180A1 (hu) |
DE (1) | DE60121096T2 (hu) |
ES (1) | ES2264679T3 (hu) |
HU (1) | HUP0101666A3 (hu) |
IL (1) | IL142707A0 (hu) |
NZ (1) | NZ511354A (hu) |
ZA (1) | ZA200103365B (hu) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8815951B2 (en) * | 1996-08-13 | 2014-08-26 | The Regents Of The University Of California | Inhibitors of epoxide hydrolases for the treatment of inflammation |
US6693130B2 (en) * | 1999-02-18 | 2004-02-17 | Regents Of The University Of California | Inhibitors of epoxide hydrolases for the treatment of hypertension |
GB0107383D0 (en) * | 2001-03-23 | 2001-05-16 | Univ Edinburgh | Lipid profile modulation |
EP1370268B1 (en) * | 2001-03-23 | 2009-07-15 | Corcept Therapeutics, Inc. | Methods for treating stress disorders using glucocorticoid receptor-specific antagonists |
GB0121709D0 (en) * | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
DE60230818D1 (de) * | 2001-09-24 | 2009-02-26 | Imp Innovations Ltd | Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit |
CA2471363C (en) | 2001-12-21 | 2014-02-11 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US8058233B2 (en) * | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
BR0308904A (pt) * | 2002-04-10 | 2005-05-03 | Lilly Co Eli | Método de tratamento de gastroparesia, e, uso de um composto de glp-1 |
WO2003093829A1 (en) * | 2002-05-02 | 2003-11-13 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with neurotensin receptor 2 (nt2) |
AU2003229736A1 (en) * | 2002-05-02 | 2003-11-17 | Bayer Aktiengesellschaft | Diagnostics and therapeutics for diseases associated with neurotensin receptor 1 (nt1) |
JP2006506366A (ja) * | 2002-10-18 | 2006-02-23 | ファイザー・プロダクツ・インク | カンナビノイド受容体リガンドおよびその使用方法 |
US8066997B2 (en) * | 2002-12-20 | 2011-11-29 | Anders Nykjaer | Modulation of activity of neurotrophins |
GB0300571D0 (en) * | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
JP2006519229A (ja) * | 2003-02-13 | 2006-08-24 | アルバート・アインシュタイン・カレッジ・オヴ・メディシン・オヴ・イェシヴァ・ユニヴァーシティ | 視床下部内の長鎖脂肪アシルCoAレベルの変調による摂食量およびグルコース産生量の調節 |
US20050222040A1 (en) * | 2004-04-05 | 2005-10-06 | Blm Group, Inc. | Vertebrate peptide modulators of lipid metabolism |
WO2006041922A2 (en) * | 2004-10-08 | 2006-04-20 | Dara Biosciences, Inc. | Agents and methods for administration to the central nervous system |
WO2006088798A2 (en) * | 2005-02-14 | 2006-08-24 | Albert Einstein College Of Medicine Of Yeshiva University | Modulation of hypothalamic atp-sensitive potassium channels |
GB0511986D0 (en) * | 2005-06-13 | 2005-07-20 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
TWI428346B (zh) * | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
LT3225251T (lt) * | 2006-12-21 | 2020-04-10 | H. Lundbeck A/S | Proneurotrofinų veiklos moduliavimas |
WO2009033808A2 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
US20100173829A1 (en) * | 2008-11-07 | 2010-07-08 | Aston University | Glycoproteins Having Lipid Mobilizing Properties and Therapeutic Uses Thereof |
JP5759379B2 (ja) | 2008-12-05 | 2015-08-05 | アンジオケム インコーポレーテッド | ニューロテンシンまたはニューロテンシンアナログおよびその使用 |
WO2011156557A2 (en) * | 2010-06-11 | 2011-12-15 | Thomas James B | Compounds active at the neurotensin receptor |
RU2013103763A (ru) | 2010-07-02 | 2014-08-10 | Ангиохем Инк. | Короткие и содержащие d-аминокислоты полипептиды для терапевтических конъюгатов и их применения |
US8476221B2 (en) * | 2011-03-18 | 2013-07-02 | Halimed Pharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders |
CN103308670B (zh) * | 2012-03-08 | 2017-06-09 | 思芬构技术有限公司 | 用于预测对象患糖尿病和/或代谢综合征的风险的方法 |
MY188344A (en) | 2012-03-09 | 2021-12-01 | Biotropics Malaysia Berhad | Extract formulations of rhodamnia cinerea and uses thereof |
US9822366B2 (en) | 2012-11-02 | 2017-11-21 | The Brigham And Women's Hospital, Inc. | Sortilin 1 is a novel inducer of vascular calcification |
WO2014071128A1 (en) | 2012-11-02 | 2014-05-08 | The Brigham And Women's Hospital, Inc. | Macrophage-derived matrix vesicles: an alternative mechanism for microcalcification in atherosclerotic plaques |
SI3380495T1 (sl) * | 2015-11-24 | 2022-01-31 | Transfert Plus, S.E.C. | Peptidne spojine in peptidni konjugati za zdravljenje raka z receptorsko posredovano kemoterapijo |
US10473670B2 (en) * | 2016-02-25 | 2019-11-12 | University Of Kentucky Research Foundation | Method of predicting obesity comprising measuring neurotensin |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4110321A (en) | 1976-07-12 | 1978-08-29 | Folkers Karl | Synthetic tridecapeptide [Gln4 ]-neurotensin having hormonal activity |
US5217953A (en) | 1990-11-30 | 1993-06-08 | The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | Vasoactive intestinal peptide antagonist |
US5250558A (en) | 1992-01-28 | 1993-10-05 | Merck & Co., Inc. | Substituted triazolinones, triazolinethiones, and triazolinimines as neurotensin antagonists used to treat psychosis |
US5204354A (en) | 1992-02-14 | 1993-04-20 | Merck & Co., Inc. | Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders |
US5407916A (en) | 1993-02-16 | 1995-04-18 | Warner-Lambert Company | Neurotensin mimetics as central nervous system agents |
FR2711140B1 (fr) | 1993-10-12 | 1996-01-05 | Sanofi Sa | 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant. |
FR2760750B1 (fr) | 1997-03-17 | 1999-05-28 | Sanofi Sa | Recepteur humain a la neurotensine de type 2(hnt-r2) |
US6008050A (en) | 1997-04-02 | 1999-12-28 | Smithkline Beecham Corporation | Human neurotensin receptor type 2 and splice variants thereof |
US6274720B1 (en) * | 1997-12-31 | 2001-08-14 | Incyte Genomics, Inc. | Human preproneurotensin/neuromedin N |
US6420137B1 (en) | 1998-11-25 | 2002-07-16 | American Home Products Corporation | Nucleic acid encoding human neurotensin subtype 2 receptor |
-
2001
- 2001-04-19 IL IL14270701A patent/IL142707A0/xx unknown
- 2001-04-24 KR KR1020010021980A patent/KR20010098829A/ko not_active Application Discontinuation
- 2001-04-24 AU AU38888/01A patent/AU3888801A/en not_active Abandoned
- 2001-04-24 US US09/841,276 patent/US6699832B2/en not_active Expired - Fee Related
- 2001-04-25 CA CA002345180A patent/CA2345180A1/en not_active Abandoned
- 2001-04-25 ZA ZA200103365A patent/ZA200103365B/xx unknown
- 2001-04-26 HU HU0101666A patent/HUP0101666A3/hu unknown
- 2001-04-26 NZ NZ511354A patent/NZ511354A/xx unknown
- 2001-04-27 EP EP01303855A patent/EP1157695B1/en not_active Revoked
- 2001-04-27 DE DE60121096T patent/DE60121096T2/de not_active Revoked
- 2001-04-27 AT AT01303855T patent/ATE331518T1/de not_active IP Right Cessation
- 2001-04-27 JP JP2001130680A patent/JP2002275092A/ja active Pending
- 2001-04-27 ES ES01303855T patent/ES2264679T3/es not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
NZ511354A (en) | 2003-03-28 |
ATE331518T1 (de) | 2006-07-15 |
KR20010098829A (ko) | 2001-11-08 |
JP2002275092A (ja) | 2002-09-25 |
HU0101666D0 (en) | 2001-06-28 |
CA2345180A1 (en) | 2001-10-27 |
DE60121096D1 (de) | 2006-08-10 |
HUP0101666A2 (hu) | 2002-02-28 |
US6699832B2 (en) | 2004-03-02 |
DE60121096T2 (de) | 2006-12-07 |
IL142707A0 (en) | 2002-03-10 |
ZA200103365B (en) | 2002-10-25 |
EP1157695A1 (en) | 2001-11-28 |
AU3888801A (en) | 2001-11-01 |
EP1157695B1 (en) | 2006-06-28 |
ES2264679T3 (es) | 2007-01-16 |
US20010046956A1 (en) | 2001-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0101666A3 (en) | Methods of treating obesity using a neurotensin receptor ligand | |
GB0023032D0 (en) | Downhole apparatus | |
IL153884A0 (en) | Capsaicin receptor ligands | |
GB0309655D0 (en) | Methods and apparatus for creating a user interface using property paths | |
EP1412599A4 (en) | DEVICE WITH DOUBLE LOCKING MEANS | |
HK1054498A1 (zh) | 按摩器 | |
HK1041541A1 (zh) | 鑑別使用人的靈活方法 | |
GB2364080B (en) | Downhole vibrator | |
GB2392186B (en) | Apparatus for use in a wellbore | |
EP1406631A4 (en) | DOPAMINE RECEPTOR LIGANDS AND CORRESPONDING THERAPEUTIC METHODS | |
IL161005A0 (en) | Neuroprotective treatment methods using selective inos inhibitors | |
EP1348053A4 (en) | SEWING APPARATUS | |
EP1322727A4 (en) | METHOD FOR TREATING HYDROCARBONS | |
GB2366356B (en) | A turf-care apparatus | |
GB2366218B (en) | A mixing device | |
GB2363996B (en) | A coin-pushing apparatus | |
HK1041601A1 (zh) | 癌症溫熱療法設備 | |
GB0001755D0 (en) | Lock apparatus | |
GB0025116D0 (en) | Obesity treatment aid | |
EP1328549A4 (en) | FOR THE HUMANE PROSTATE-SPECIFIC G-PROTEIN RECEPTOR HPRAJ70 | |
TW510219U (en) | Massage mat | |
HUP0003346A3 (en) | A water treating apparatus | |
GB0106932D0 (en) | Toilet apparatus | |
GB0025019D0 (en) | Tiling aid apparatus | |
GB0100164D0 (en) | Novel estrogen receptor ligands and methods II |